Rare disease focus Target nephrology and hepatology stakeholders with sparsentan and other pipeline programs addressing FSGS, IgAN, PKU, NGLY1 deficiency, and Alagille syndrome to align with Retrophin's mission of delivering therapies for rare diseases and unmet medical needs.

Commercial backbone Leverage existing revenue from Chenodal, Cholbam, Thiola and THIOLA EC to establish credibility with payers and healthcare providers, enabling partnerships around expanded indications, co-promotion, or access programs in rare kidney and biliary disorders.

Clinical collaboration Propose co-development, research alliances, or strategic partnerships with academic centers and patient advocacy groups to accelerate late-stage trials for sparsentan and pipeline candidates, highlighting Retrophin’s emphasis on patient focus and scientific excellence.

Data and outcomes Offer real-world evidence support, patient registries, and health economics outcomes research to demonstrate value for new therapies in nephrology and hepatology, aiding payer discussions and market access for upcoming launches.

Global integration Position as a global, fully-integrated biopharma with a pipeline and commercial footprint to attract international licensing, expansion, and manufacturing partnerships that can scale production and distribution of approved and late-stage therapies.